Global Duchenne Muscular Dystrophy Clinical Trial Pipeline Report 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Duchenne Muscular Dystrophy Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.

Duchenne Muscular Dystrophy Pipeline Highlights – 2019, provides most
up-to-date information on key pipeline products in the global Duchenne
Muscular Dystrophy market. It covers emerging therapies for Duchenne
Muscular Dystrophy in active clinical development stages including early
and late stage clinical trials. The pipeline data presented in this
report helps executives for tracking competition, identifying partners,
evaluating opportunities, formulating business development strategies,
and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Duchenne Muscular Dystrophy pipeline products by
clinical trial stages including both early and late stage development –
phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical
trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Duchenne Muscular Dystrophy pipeline products by
their dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Duchenne Muscular Dystrophy pipeline products by the
company.

Short-term Launch Highlights:

Find out which Duchenne Muscular Dystrophy pipeline products will be
launched in the US and Ex-US till 2024.

Summary:

• Duchenne Muscular Dystrophy phase 3 clinical trial pipeline products
• Duchenne Muscular Dystrophy phase 2 clinical trial pipeline products
• Duchenne Muscular Dystrophy phase 1 clinical trial pipeline products
• Duchenne Muscular Dystrophy preclinical research pipeline products
• Duchenne Muscular Dystrophy discovery stage pipeline products
• Duchenne Muscular Dystrophy pipeline products short-term launch
  highlights

Key Topics Covered:

1. Duchenne Muscular Dystrophy Pipeline by Stages

2. Duchenne Muscular Dystrophy Phase 3 Clinical Trial Insights

3. Duchenne Muscular Dystrophy Phase 2 Clinical Trial Insights

4. Duchenne Muscular Dystrophy Phase 1 Clinical Trial Insights

5. Duchenne Muscular Dystrophy Preclinical Research Insights

6. Duchenne Muscular Dystrophy Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/i1i8fg

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs, Clinical
Trials, Musculoskeletal
Disorders Drugs